Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
63
resultados
Última actualización
28/08/2026 [06:45:00]
Resultados 50 a 63 de 63
Resumen de: US20260218197A1
The present invention provides a novel secretion reducing agent and novel secretion reducing method for reducing extracellular vesicle secretion from cells. The extracellular vesicle secretion reducing agent of the present invention is characterized in that it contains an inhibitor of a serine synthesis pathway. The cells are, for example, cancer cells such as colorectal cancer cells, lung cancer cells, melanoma cells, breast cancer cells, pancreas cancer cells, and multiple myeloma cells.
Resumen de: US20260217723A1
0000 Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Resumen de: AU2025210712A1
Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.
Resumen de: WO2026157434A1
Provided are a CD180-targeting chimeric antigen receptor and the use thereof. By means of flow cytometry, degranulation assays and assays of cytokines secreted by T cells, it is proved that T cells modified with the chimeric antigen receptor have potent killing effect on acute myeloid leukemia cells that express CD180, and have no killing effect on cells that do not express CD180, effectively preventing off-target effect; and the colony formation ability of umbilical cord blood-derived CD34+ hematopoietic stem/progenitor cells is not affected, achieving safety. The chimeric antigen receptor CD180 scFv-CD8α-4-1BB-CD3ζ can be used for the treatment of CD180-positive hematological tumors.
Resumen de: WO2026157435A1
Provided are anti-human CD180 antibodies and the use thereof. The provided anti-human CD180 antibodies A24C9 and C12F11 have high affinity to human CD180 protein, with Kd values thereof being 0.4748 nM and 78.19 nM respectively; said antibodies have high binding specificity and can specifically recognize human CD180-positive acute myeloid leukemia (AML) cell lines (OCI-AML2, MV4-11, THP1) and human CD180-positive B-cell lymphoma cell lines (Daudi, BJAB, Nalm6), and have no cross-reactivity with various human CD180-negative cell lines (K562, NB4, Kasumi1, TF1, NK92, Jurkat, SupT1 and MM1S). Said antibodies can be used not only for detecting the expression of human CD180 protein, but also for immunotherapy alone or in combination with other methods, and have diagnostic and therapeutic values for tumors, autoimmune diseases, graft-versus-host diseases and inflammatory diseases.
Resumen de: WO2026161509A2
The present disclosure provides methods of treating an autoimmune disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a bispecific CD20xCD3 antibody comprising a first antigen-binding arm that specifically binds CD20 and a second antigen-binding arm that specifically binds CDS (e.g., odronextamab or a bioequivalent thereof). In some embodiments, the disclosed methods treat both an autoimmune disorder (e.g., aHUS) and a B-cell cancer (e.g., lymphoma).
Resumen de: WO2026159094A1
PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial treatment typically involves reducing immunosuppressive therapy and using rituximab, with further options including immunochemotherapy or adoptive cellular therapy for refractory cases. Now, the inventors hypothesized that the concentration of sCD95L could exert a biological function and affect clinical outcomes by modulating the immune response. Using the K-VIROGREF cohort, they dosed by ELISA sCD95L in 175 transplant patients with PTLD and 16 transplant controls. Plasma levels of sCD95L were elevated in transplant recipients. Interestingly, in patients with PTLD who expressed higher concentrations of sCD95L, clinical outcomes were better than those with lower concentrations, especially in patients with central nervous system (CNS) involvement where sCD95L was a marker of good prognostic. Thus, sCD95L is a novel prognostic marker that might guide treatment strategies in patients with PTLD, especially in those with CNS involvement. Therefore, the present invention relates to the use of soluble CD95L as a prognostic marker in post-transplant lymphoproliferative disorders.
Resumen de: US20260216327A1
0000 Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
Resumen de: US20260216138A1
0000 Provided is a composition for targeting OTUD7B. The composition includes a component sufficient to block or reduce OTUD7B-mediated deubiquitination of GβL in a cell. The component can include 7Bi and variants thereof. Also provided are methods of treating cancer and related conditions, including administering to a cancer patient a OTUD7B catalytic inhibitor, including a 7Bi or variant thereof.
Resumen de: US20260216204A1
0000 The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith.
Resumen de: US20260218307A1
Described herein are methods for diagnosing and treating mycosis fungoides (MF) and cutaneous T cell lymphoma (CTCL), e.g., for making a differential diagnosis of CTCL/MF versus other skin conditions.
Resumen de: EP4782010A1
0001 The use of an anti-CD20 antibody-drug conjugate or a pharmaceutical combination thereof in the preparation of a drug for treating non-Hodgkin lymphoma. The pharmaceutical combination comprises the anti-CD20 antibody-drug conjugate and at least one therapeutic agent. Compared with existing clinical second-line standard therapies, combination therapy using the anti-CD20 antibody-drug conjugate or the pharmaceutical combination comprising same has a better therapeutic effect.
Nº publicación: EP4782436A2 29/07/2026
Solicitante:
OHIO STATE INNOVATION FOUNDATION [US]
HENDRIX COLLEGE [US]
OHIO STATE INNOVATION FOUNDATION
Hendrix College
Resumen de: EP4782436A2
Disclosed herein are compounds, 6-substituted-2-(1,1'-biphenyl-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
BOPI
Sede Electrónica
